US-Listed Public Company Profile built from SEC and market records · June 2026

Revolution Medicines, Inc. (RVMD)

$183.90 -1.65% NASDAQ: RVMD · 15-min delayed

REDWOOD CITY, California
Public · NASDAQ: RVMD
883 employees

Visit website Follow

$40.2BMarket cap

$0Revenue · FY2025

-$1.1BNet income

883Employees

RVMDNASDAQ

2020IPO

About Revolution Medicines, Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: RVMD
Employees: 883
IPO date: Feb 13, 2020
Headquarters: 700 SAGINAW DR
REDWOOD CITY, California 94063
Phone: 650-481-6801
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300JU3X0LBCQ65892

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Is Revolution Medicines, Inc. an American company? Yes. Revolution Medicines, Inc. is incorporated in Delaware, United States and headquartered in Redwood City, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Registry IDs

Ticker: RVMD Nasdaq
SEC CIK: 1628171
LEI: 549300JU3X0LBCQ65892
EIN: 472029180
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Revolution Medicines, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/revolution-medicines-inc/"><img src="https://americancompanies.com/badge/revolution-medicines-inc.svg" alt="Revolution Medicines, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Revolution Medicines, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $0
Net income: -$1.1B
Total assets: $2.4B
Market cap: $40.2B

Source: SEC EDGAR · updated Jun 8, 2026

NASDAQ: RVMD

$183.90 -1.65%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$42.51 $221.15

52-week range

Market cap: $40.2B
Shares outstanding: 218.8M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Feb 13, 2020

Revolution Medicines, Inc. (RVMD) Stock Price

Reported a net loss of $1.1B in FY2025.
Trading 17% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Revolution Medicines, Inc..

Write a review

Newsroom

News about Revolution Medicines, Inc.

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight GlobeNewswire Inc. · 2026-10-26 · positive These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead The Motley Fool · 2026-10-15 · neutral Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool · 2026-09-11 · positive New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer GlobeNewswire Inc. · 2026-09-02 · positive Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? The Motley Fool · 2026-08-28 · positive Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib) GlobeNewswire Inc. · 2026-08-26 · positive

News & sentiment via Polygon.io

FAQ

Revolution Medicines, Inc.: frequently asked questions

Is Revolution Medicines, Inc. an American company?

Yes — Revolution Medicines, Inc. is an American company. Revolution Medicines, Inc. is incorporated in Delaware, United States and headquartered in Redwood City, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Where is Revolution Medicines, Inc. incorporated?

Revolution Medicines, Inc. is legally incorporated in Delaware, United States, according to its GLEIF legal-entity record.

Who owns Revolution Medicines, Inc.?

Revolution Medicines, Inc. reports no parent company in its legal-entity record — it is independently owned rather than a subsidiary.

Is Revolution Medicines, Inc. traded on a US stock exchange?

Yes — Revolution Medicines, Inc. trades under the ticker RVMD on the NASDAQ.

Where is Revolution Medicines, Inc. headquartered?

Revolution Medicines, Inc. is headquartered in Redwood City, California, United States.

Is Revolution Medicines, Inc. publicly traded?

Yes — Revolution Medicines, Inc. is a publicly traded company. Its stock trades under the ticker symbol RVMD on the NASDAQ.

What does Revolution Medicines, Inc. do?

Revolution Medicines, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.